An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.

ABSTRACT:

Background

Many patients with Parkinson's disease (PD) experience depression.

Objective

Evaluate pimavanserin treatment for depression in patients with PD.

Methods

Pimavanserin was administered as monotherapy or adjunctive therapy to a selective serotonin reuptake inhibitor or serotonin/noradrenaline reuptake inhibitor in this 8-week, single-arm, open-label phase 2 study (NCT03482882). The primary endpoint was change from baseline to week 8 in Hamilton Depression Scale-17-item version (HAMD-17) score. Safety, including collection of adverse events and the Mini-Mental State Examination (MMSE) and Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) scores, was assessed in patients who received ≥1 pimavans

SUBMITTER: DeKarske D 

PROVIDER: S-EPMC7683094 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature